CoLumbo
Smart Soft HealthcareProduct specifications |
Information source:
Vendor
Last updated: May 22, 2023 |
General | |
---|---|
Product name | CoLumbo |
Company | Smart Soft Healthcare |
Subspeciality | Spine |
Modality | MR |
Disease targeted | Disk herniation (Protrusion / Extrusion modifiers), Central Spinal Stenosis (CSS), Shizas and Lee morphological grading, foraminal stenosis, decreased vertebral body heights, decreased vertebral disk height, hypo/hyperlordosis, nerve root impingement, listhesis |
Key-features | Lumbar spine annotation, smart navigation, editable report, editable separate pathology report, measurement calculation based on segmentation |
Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion |
Data characteristics | |
Population | Europe - MRI lumbar spine studies, age – 18 to 70 (included) USA - MRI lumbar spine studies, age – 18+ |
Input | Lumbar spine MR, Magnetic Field Strength 1,5-3T. At least one sagittal T2w sequence containing 5 slices or more. Scanning Sequence – SE |
Input format | DICOM |
Output | Segmentation overlay, probability score per pathology, draft radiology report, image annotations, table of quantified values, list with measurements. |
Output format | DICOM, DICOM PDF |
Technology | |
Integration | Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application |
Deployment | Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based |
Trigger for analysis | Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc. |
Processing time | 10 - 60 seconds |
Certification | |
CE
|
Certified,
Class IIa
, MDD
|
FDA
|
510(k) cleared, Class II |
Market presence | |
On market since | 03-2021 |
Distribution channels | Incepto, CARPL.ai, deepcOS, Philips AI manager, Blackford, Osimis |
Countries present (clinical, non-research use) | 9 (USA, Germany, Italy, France, Spain, Belgium, Netherlands, Austria, Switzerland) |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | Pay-per-use, Subscription |
Based on | Number of analyses |
Evidence | |
Peer reviewed papers on performance | |
Non-peer reviewed papers on performance | |
Other relevant papers |